AASCIT - Journal - All Issues

ISSN: 2375-3900

American Journal of Pharmacy and Pharmacology

The Journal

Manuscript Information

Hematological Studies in Egyptian Thalassemic Children Infected with Hepatitis C Virus

American Journal of Pharmacy and Pharmacology
Vol.4 , No. 6, Publication Date: Nov. 25, 2017, Page: 59-64

587 Views Since November 25, 2017, 583 Downloads Since Nov. 25, 2017

Paper in PDF (364K)

Follow on

Authors

[1]	Mahmoud Gomaa, Microbiology Section, Faculty of Science, Tanta University, Tanta, Egypt.
[2]	Mostafa Mohamed El-Sheekh, Microbiology Section, Faculty of Science, Tanta University, Tanta, Egypt.
[3]	Ahmed S. El-Shafey, Microbiology Section, Faculty of Science, Tanta University, Tanta, Egypt.
[4]	Metwally Abdel-Azeem Metwally, Microbiology Section, Faculty of Science, Tanta University, Tanta, Egypt.
[5]	Mohamed Ramadan El-Shanshory, Pediatrics Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
[6]	Manal Abdel-Wahed Eid, Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.

Abstract

The present study was conducted to evaluate the efficiency of natural Spirulina preparation on some hematological parameters in thalassemic children infected with hepatitis C virus (HCV). Twenty five (25) Egyptian thalassemic children infected with HCV (12 male, and 13 female children), aged from 3 to 8 years were subjected in this study. Volunteers were supplied with dried Spirulina (250 mg /kg /day) by oral uptake with their usual thalassemic drugs. Throughout 6 months treatment, Red blood cell count, hemoglobin level, serum ferritin and blood transfusion intervals were assessed. This study proved that there was improvement of the treated thalassemic children after 6 months from uptaking Spirulina

Keywords

Hepatitis C Virus, Thalassemia, Spirulina, Red Blood Cell Count, Hemoglobin and Serum Ferritin

Reference

[01]	John, K. (2011): Complications of Thalassemia. Mayo Clinic.
[02]	Tom, L.; Xu, H.; and Hue, L. (2008): Treatment of iron overload in thalassemia. Pediatr. Endocrinol. Rev., 1: 208-213.
[03]	Clair, S. (2011): Thalassemia Complications. Thalassemia, Open Publishing.
[04]	Wambua, S. (May 2006): The Effect of α + β -Thalassaemia on the Incidence of Malaria and Other Diseases in Children Living on the Coast of Kenya. PLos. Medicine, 3: 158-162.
[05]	Tassiopoulos, S. (2005): Does heterozygous beta-thalassemia confer a protection against coronary artery disease?. Annals of the New York Academy of Sciences, 1054: 467-470.
[06]	Claude, O. (2011): Separating Thalassemia Trait and Iron Deficiency by Simple Inspection. American Society for Clinical Pathology, 118: 402-407.
[07]	Harrison, K. (2008): Harrison's Principles of Internal Medicine, 17^th Ed., McGraw-Hill medical, p. 776.
[08]	Vonshak, A. (1997): Spirulina platensis (Arthrospira); Physiology, Cell-biology and Biotechnology. London: Taylor & Francis, p.: 162.
[09]	Kapoor, R.; and Mehta, U. (1993): Effect of supplementation of blue green alga (Spirulina) on outcome of pregnancy in rats. Plant Foods Hum Nutr., 43: 29–35.
[10]	Mathew, B.; Sankaranarayanan, R.; Nair, P.; and Varghese, C. (1995): Evaluation of chemoprevention of oral cancer with Spirulina fusiformis. Nutr Cancer, 24: 197-202.
[11]	Sánchez, M. (2007): Spirulina (Arthrospira): An edible microorganism, a review. http:// www.javeriana.edu.co/ universitas_scientiarum/vol8n1/J_bernal.html.
[12]	Mani, U.; Desai, S.; and Iyer, U. (2000): Studies on the long-term effect of Spirulina supplementation on serum lipid profile and glycated proteins in NIDDM patients. J. Nutr. Functional. Med. Fds., 2: 25-35.
[13]	Health Systems Profile- Egypt, (2006): Regional Health Systems Observatory- EMRO, World Health organization
[14]	Costa J. A. C., Morais M. G. Microalgae for food production. In: Soccol C. R., Pandey A., Larroche C., editors.(2013): Fermentation Process Engineering in the Food Industry. Taylor & Francis; 2013. p. p. 486
[15]	Cheesbroug, Monica. (2005): Hematological Tests. in: District laboratory practice in tropical countries part 2. 2nd ed. Cambridge university press, UK, PP: 38: 326
[16]	Ghosh, A.; Woo, J.; Wan, C.; Machenry, C.; Wong, V.; and Ma, H. (1985): Evaluation of a Prenatal Screening Procedure for β-Thalassemia Carriers in a Chinese Population Based on the Mean Corpuscular Volume (MCV). Prenat. Diagn., 5 (1): 59-65.
[17]	Vliegen, J.; Paeshuyse, T.; De Burghgraeve, L.; and Lehman, M. (2009): Substituted imidazopyridines as potent inhibitors of HCV replication. In: J. of Hepatology, 50: 999-1009.
[18]	Biggins, J.; Trotter, J.; Gralla, J.; and Burton J. (2013): Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation. In: J. of Hepatology, 58: 969-976.
[19]	Fisicaro, C.; Valdatta, M.; Massari, E.; and Loggi, L. (2012): Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. In: J. of Gastroenterology, 143: 1576-1585.
[20]	Samri, A.; Roque-Afonso, O.; Beran, M.; Tateo, E.; and Teicher, C. (2009): Preservation of immune function and anti-hepatitis C virus (HCV) immune responses after liver transplantation in HIV–HCV coinfected patients (ANRS-HC08 “THEVIC” trial). In: J. of Hepatology, 51: 1000-1009.
[21]	Galambrun, C.; Pondarré, Y.; and Bertrand, A. (2013): French Multicenter 22-Year Experience in Stem Cell Transplantation for Beta-Thalassemia Major: Lessons and Future. In: J. of Biology of Blood and Marrow Transplantation, 19: 62-68.
[22]	Fung, Y.; Xu, F.; Trachtenberg, I.; and Odame, J. (2012): Inadequate Dietary Intake in Patients with Thalassemia. In: J. of the Academy of Nutrition and Dietetics, 112: 980-990.